What a Patent Actually Protects (and What It Doesn’t)

Last updated 15 hours ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

Ask a first-time inventor what a patent does, and you’ll usually hear some version of this: it protects my idea so nobody can steal it.

That sounds right. It’s also wrong on almost every word.

A U.S. patent does not protect an idea. Nor does it give you permission to sell anything. And it certainly doesn’t guarantee that nobody copies you.

What it grants is narrower, stranger, and more powerful than most people expect.

Here’s the core of it, stated plainly. A patent is a government grant of a right to exclude others. It lets you stop other people from doing specific things with a specific invention, inside the United States, for a limited time.

That’s the whole of it. Everything else in this article is a footnote to that sentence.

So if you get a patent, what exactly can you stop people from doing? And what are they still free to do despite your patent? Those are the questions worth answering, because the gap between the two is where fortunes and lawsuits live.

A Right to Exclude, Not a Right to Do

Start with the statute, because the wording matters here. Title 35 of the U.S. Code, section 154, says a patent grants the owner “of the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States or importing the invention into the United States.” The statute defines the grant as a power to exclude.

Notice what’s missing. Nowhere does it say the patent holder may make, use, or sell the invention. The patent is a fence, not a license.

Think of it this way. Owning a patent is like owning a stretch of road you can block. It does not mean you’re allowed to drive on it.

The consequences are real. A pharmaceutical company can hold airtight patents on a new drug and still be barred from selling it, because the FDA can block marketing until safety and efficacy are established. An engineer can patent a clever improvement to an engine and still be unable to build it, because the underlying engine is covered by someone else’s earlier patent. To practice the improvement, you’d need a license from both patent holders.

The enforcement side lives in section 271. It says “whoever without authority makes, uses, offers to sell, or sells any patented invention, within the United States or imports into the United States any patented invention” during the patent’s term infringes the patent.

Read those verbs carefully, because they are the entire list of things you can stop: make, use, offer to sell, sell, import. If someone does one of those with an invention covered by your claims, you can sue. If they do something else, you generally can’t.

And here’s the part that surprises people: intent doesn’t matter for basic infringement. Section 271(a) says nothing about copying or knowledge; it’s strict liability.

Someone who independently invents the exact same thing, having never seen your patent, still infringes if their product falls within your claims. The system protects your claimed invention against honest re-inventors just as firmly as against copycats.

The Patent Bargain, and Why It Expires

Why would a government hand out the power to block competitors at all? Because it’s getting something in return.

The deal is a trade. You get a temporary right to exclude. In exchange, you tell the public exactly how your invention works, in enough detail that a skilled person could build it. When the term ends, everyone gets to use it freely.

That’s why patents die on a clock. Section 154 sets the term: the term of a patent shall be 20 years from the date on which the application for the patent was filed in the United States. The USPTO’s examining manual calls this the twenty-year term and works out how it’s counted for continuation and international filings. Design patents run differently: fifteen years from grant for applications filed on or after May 13, 2015.

The disclosure requirement is the reader’s side of the bargain. Claims must be, in the manual’s words, “fully supported by the description.” A patent has to teach, not just gesture. That teaching becomes public the day the patent publishes, and it stays public forever, which is how a competitor can read your patent, learn from it, and legally design something that avoids it.

The three kinds of patents each fence off a different thing.

Source: Patent Lawyer Magazine’s overview of patent types and USPTO term rules.

A single product can carry all three. A smartphone might hold utility patents on its circuitry and battery chemistry, a design patent on the shape of the shell, and a design patent on the icon layout. The functional insides and the pretty outside are protected by different rules that stop at different places.

What the Claims Cover, and Nothing More

Here’s where people get tripped up. A patent document runs pages: background, diagrams, examples, discussion. Almost none of that is the protected zone.

The protected zone is the claims. Those numbered sentences at the end. The manual is blunt about it: the claim or claims must define the matter for which protection is sought. The claims are the fence line; the rest of the document is scenery that helps a court read the fence.

This has a hard edge. If your claims list six elements, and a competitor’s product has five of them but skips the sixth, the competitor generally doesn’t infringe. Even if their product does the same job just as well. The claim is a checklist, and every box has to be ticked.

Which is why competitors read your claims like a treasure map in reverse, looking for the one element they can leave out. That practice, studying the claims and deliberately building something outside them, is called designing around. It’s not cheating. It’s exactly what the system is built to encourage.

Now, what can go inside a claim in the first place? The gateway is section 101: “Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.” Four categories, plus improvements to them.

The USPTO reads those categories as a hard boundary. The manual says section 101 “enumerates four categories of subject matter that Congress deemed to be appropriate subject matter for a patent: processes, machines, manufactures and compositions of matter.” If a claim covers something outside those four, it’s out, no matter how new. In one Federal Circuit case, a transitory signal was held not patentable because a fleeting waveform doesn’t fit any of the categories.

The Things Patents Can Never Fence Off

On top of the four categories sits an old judge-made rule: you cannot patent a law of nature, a natural phenomenon, or an abstract idea. These are the building blocks of everything, and letting one person own them would choke off invention rather than spur it.

Two Supreme Court cases from the last decade set the modern line, and they’re worth knowing because they define what stays public forever.

In the 2014 case Alice Corp. V. CLS Bank International, the Court looked at claims covering a scheme for settling financial trades through a middleman. It called that idea “a fundamental economic practice long prevalent in our system of commerce,” and held that running it on a generic computer didn’t make it patentable.

You can’t take an old idea, add “on a computer,” and call it an invention.

In the 2012 case Mayo v. Prometheus, the claims described the correlation between a patient’s blood levels of a drug and whether the dose was working. The Court found those claims effectively claim natural laws or natural phenomena, namely, the correlations between thiopurine metabolite levels and the toxicity and efficacy of thiopurine drugs, and therefore are not patentable. The relationship exists in the body; nobody invented it.

So the idea of online shopping isn’t patentable, though a particular technical method of processing an order might be. Hedging risk, as a concept, is out of reach too, and so is the natural link between a gene and a disease.

What can be patented is a concrete application that does something inventive with those raw materials.

There’s also a line Congress drew by hand. The America Invents Act says “no patent may issue on a claim directed to or encompassing a human organism.” You cannot patent a human being, however the claim is dressed up.

When a Competitor’s Design-Around Still Infringes: Polaroid, Kodak, and LEGO

The best way to see where these fences fall is to watch a real one get tested. Two stories do it, one American and one from across the border.

The American one is Polaroid Corp. V. Eastman Kodak Co. Kodak entered the instant-camera market in 1976.

Polaroid sued within months, alleging infringement of a dozen patents on instant photography, and claimed lost profits that ran, by some accounts, into billions of dollars.

Kodak’s defense was that it hadn’t copied. It had built its own cameras and its own film chemistry, different in many technical ways. This is the design-around argument in its strongest form: we solved the same problem differently.

It didn’t work. After a long trial, a federal court in 1985 found Kodak liable for infringing seven Polaroid patents. The opinion crawled through the technical weeds, at one point analyzing where an “acid layer” sat inside Kodak’s film stack, and concluded that Kodak’s “designed‑around” film still landed inside Polaroid’s claims. The court then issued an injunction forcing Kodak out of the instant-photography business entirely.

The fallout reached ordinary people. An estimated 16 to 16.5 million Kodak instant cameras turned into paperweights once film stopped shipping, and Kodak had to run refund and exchange programs. The damages, resolved in the early 1990s, ran to roughly 909 to 925 million dollars, at the time the largest satisfied patent judgment in U.S. history.

The lesson: patents don’t protect the broad idea of “instant photos.” They protect specific claimed implementations. But those claims can be drafted broadly enough to swallow a rival’s independent design. A different-looking product is not automatically a safe one.

The mirror-image lesson comes from a Canadian case, so treat it as comparative rather than U.S. law. LEGO tried to keep competitors from making compatible bricks after its patents on the stud-and-tube coupling had expired.

Having lost patent protection, LEGO reached for trademark law instead.

The court refused. The Federal Court of Appeal held that a primarily functional shape cannot be a valid trademark, reasoning that granting one would confer a perpetual, patent-like monopoly after the patents had expired — contrary to the policy behind the functionality doctrine. The Supreme Court of Canada also used the case to uphold the constitutional validity of section 7(b) of the Trade-marks Act, Canada’s federal passing-off provision, as a proper exercise of federal trade and commerce power. The appeal was dismissed with costs.

That is the expiration bargain made visible. Once a patent on a functional feature runs out, competitors are free to copy the function, and no other flavor of intellectual property can be stretched to plug the gap.

The Fences Stop at the Border and the Clock

A U.S. patent is a U.S. thing. Section 271 keeps saying it: acts “within the United States,” imports “into the United States.” The territory is baked into the statute.

So a competitor who manufactures your patented product entirely abroad and sells it only in a country where you hold no patent is not infringing your U.S. patent. If you want protection in Germany or Japan, you need patents there.

There’s a narrow exception. Section 271(f) reaches people who ship most of the components of a patented invention out of the U.S. intending them to be assembled abroad in a way that would infringe if done at home. It plugs one loophole. It does not create a global patent.

For inventors who do want to go global, the Patent Cooperation Treaty is the workhorse. A 2026 WIPO analysis found that a single international application has the same legal effect as filing separately in every designated member state, and the treaty spans more than 150 countries. It buys time and a coordinated filing position; it does not create one worldwide patent. Each country still grants and enforces its own.

Now the thing that trips up nearly every startup founder: “patent pending” is not protection. Filing a provisional application lets you stamp your product patent pending, but a provisional “is not examined” and, in the USPTO’s own words, “does NOT issue as a patent.” It’s a low‑cost way to lock in an early filing date, and it lapses automatically after 12 months.

Enforceable rights arrive only after a nonprovisional is examined and granted. Until then, a competitor who copies you generally can’t be sued. Patent pending is a warning sign and an investor signal, not a legal weapon.

Even a Granted Patent Can Be Taken Back: VirnetX v. Apple

Suppose you clear every hurdle. You file first, you draft careful claims, the patent issues.

But since the America Invents Act, which switched the U.S. to a first-inventor-to-file system for applications with an effective filing date on or after March 16, 2013, a granted patent is more contingent than it used to be. A challenger can drag it before the Patent Trial and Appeal Board and try to cancel the claims.

There are two main routes. Post-grant review must be filed within nine months of grant and can attack a patent on nearly any validity ground, if at least one claim is “more likely than not” unpatentable. Inter partes review comes later and is narrower, instituted when a challenger shows a “reasonable likelihood” of winning, with a target to finish within a year.

These reviews have teeth. A patent that made it through examination is not a patent that will survive scrutiny.

The VirnetX v. Apple opinion, issued March 31, 2023, is almost eerie in its symmetry. The court noted it had “previously affirmed that Apple’s VPN On Demand feature infringed claims of U.S. Patent Nos. 6,502,135 and 7,490,151.” Apple had infringed, in other words. The court’s disposition was flat: “we vacate the district court’s judgment and remand with instructions to dismiss the case as moot. VACATED AND REMANDED.”

The infringement finding, erased, not because Apple hadn’t infringed but because the fence itself was found to have never been valid. That’s the modern shape of the right to exclude: real, but revocable.

The Gap Between Owning a Patent and Being Able to Use One

The right to exclude is only worth what you can afford to enforce, and that is where the story turns uncomfortable for ordinary inventors.

Getting the patent isn’t cheap, and it isn’t fast. USPTO data through 2024 and 2025 show first office action pendency around 20 to 22 months and total pendency near 26 months, with a backlog of hundreds of thousands of unexamined applications. In fast-moving markets, the patent can arrive after the commercial window has closed.

Enforcement in court costs far more.

Then there’s the flip side, where the right to exclude gets pointed at people who never copied anything. Gilbert Hyatt, a Nevada inventor who filed computer-related applications back in 1971 and 1972, spent decades fighting the USPTO over applications he said the office stalled and abandoned. The USPTO argued that Hyatt’s claims weren’t ripe because he hadn’t exhausted his administrative remedies by seeking a final agency decision on the applications.

At the other extreme sit the assertion entities. Comedian and podcaster Adam Carolla became a target when a company claiming a patent that arguably covered “all podcasting” sued him and others. One account of the fight noted that “Carolla and others declined to pay and were sued,” as a commenter summarizing the case described it, and Carolla raised crowdfunding money to fight for invalidation. The inventor Jerome Lemelson reportedly extracted roughly 650 million dollars in settlements from firms like Ford, Motorola, and Toyota without ever manufacturing his inventions.

Which leaves the honest answer to the question we started with. A patent lets you stop others from making, using, offering to sell, selling, or importing, inside the United States, a product or process that meets every element of your claims, for a limited term, unless the patent is later invalidated. It does not let you stop anyone from thinking about your idea, discussing it, designing around it, or building a rival product entirely abroad. And it does not, on its own, hand you the money or the time to enforce any of that.

The fence is real. Whether you can afford to patrol it, and whether it survives the first challenger who tests it, is a separate question entirely, and it’s the one the next generation of inventors will keep discovering the hard way.

Frequently Asked Questions

Does a patent let me sell my invention?

Not by itself. A patent is a right to exclude others, not a right to practice. You might still need FDA approval, other regulatory clearances, or licenses from earlier patent holders whose inventions your product builds on. It’s common to hold a valid patent on something you’re legally barred from selling.

If someone invents the same thing without copying me, do they infringe?

Yes. Basic infringement under section 271(a) is strict liability and says nothing about copying or knowledge. If a competitor independently develops something that falls within every element of your claims and makes, uses, or sells it in the United States, they infringe, even if they never saw your patent.

Does “patent pending” stop competitors from copying me?

No. Filing a provisional application lets you use the label and locks in an early filing date, but the provisional is not examined and does not issue as a patent. Enforceable rights arrive only after a nonprovisional application is examined and granted. Until then, a copier generally cannot be sued for infringement.

Can a granted patent be taken away?

It can. Through PTAB proceedings like inter partes review and post-grant review, a challenger can get claims cancelled. In the VirnetX case, a 502.8 million dollar verdict against Apple was vacated after the underlying patents were held unpatentable, even though Apple had been found to infringe. A granted patent is a strong right, not an unbreakable one.

Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.